Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

A Phase I/IIa, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of CYB003 in Participants With Major Depressive Disorder

To see complete record on, please visit this link

Id: NCT05385783

Organisation Name: Cybin IRL Limited

Overal Status: Recruiting

Start Date: July 6, 2022

Last Update: July 13, 2022

Lead Sponsor: Cybin IRL Limited

Brief Summary: The purpose of this study is to determine the safety and tolerability of ascending oral doses of CYB003 in participants with major depressive disorder (MDD).

  • Major Depressive Disorder

Total execution time in seconds: 0.2899751663208